^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SHR-4602

    i
    Other names: SHR-4602, SHR4602, SHR 4602
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Microtubule inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    17d
    A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Atridia Pty Ltd. | Initiation date: Nov 2024 --> Mar 2025
    Trial initiation date • Metastases
    |
    SHR-4602
    18d
    A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=20, Recruiting, Atridia Pty Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    SHR-4602
    26d
    A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd.
    New P2 trial • Combination therapy • Metastases
    |
    SHR-4602
    4ms
    A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Atridia Pty Ltd.
    New P1 trial • Metastases
    |
    SHR-4602
    5ms
    SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=240, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial • Metastases
    |
    SHR-4602
    over1year
    A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=133, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • HER-2 expression
    |
    SHR-4602
    over1year
    A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=133, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P1 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • HER-2 expression
    |
    SHR-4602